This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Milford, MA-based, Waters Corp. is an analytical instrument manufacturer and offers practical and sustainable products for laboratory-dependent organizations. Moreover, Waters provides analytical workflow solutions based on mass spectrometry (MS), liquid chromatography (LC) and thermal analysis technologies. The company’s products are used by pharmaceutical, life science, biochemical, industrial, academic and government customers, working in research and development, quality assurance and other laboratory applications. The company operates in Asia, Americas and Europe. Waters organizes its business into two operating segments: Waters Division and TA Division. Waters Division (88.8% of total revenues in 2019) - High Performance and Ultra Performance Liquid Chromatography (HPLC and UPLC). TA Division (11.2% of total revenues in 2019)- Thermal Analysis, Rheometry and Calorimetry.
Waters (WAT) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) fourth-quarter 2020 results are likely to reflect the impacts of product introductions and large molecule strength.
Zacks Industry Outlook Highlights: Mettler-Toledo International, Waters Corp, PerkinElmer and Bruker
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mettler-Toledo International, Waters Corp, PerkinElmer and Bruker
4 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is gaining from strong life science, pharmaceutical and academic end-market demand. Industry participants MTD, WAT, PKI, and BRKR are set to gain from rising healthcare spending and exposure to developing economies like China and India.
Waters (WAT) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 13.09% and 8.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Waters' (WAT) third-quarter 2020 results reflect benefits from strong momentum across the Americas and Europe, and improved performance in the pharmaceutical and industrial market.
Waters (WAT) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) third-quarter results are likely to reflect strength across new product cycle and the liquid chromatography space. However, coronavirus headwinds might have been concerns.
Analysts Estimate Waters (WAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Waters (WAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Mettler-Toledo, PerkinElmer, Waters and Bruker
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mettler-Toledo, PerkinElmer, Waters and Bruker
4 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is gaining from strong life science, pharmaceutical and academic end-market demand. Industry participants MTD, PKI, WAT and BRKR are set to gain from rising healthcare spending and exposure to developing economies like China and India.
Why Is Waters (WAT) Down 0.2% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Waters (WAT) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Shilpa Mete
Waters' (WAT) second-quarter results benefit from cost-cutting strategies. However, coronavirus-led disruptions remained headwinds.
Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 37.25% and 0.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Waters (WAT)
by Zacks Equity Research
Waters (WAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Waters (WAT) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) second-quarter 2020 results are likely to reflect new product introductions and large molecule strength.
Waters (WAT) Up 3.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Drab Near-Term Prospects for Scientific Instruments Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry is witnessing a slump in demand for instruments as laboratories and research facilities remain closed in the wake of the pandemic predicament.
Waters (WAT) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Waters' (WAT) first-quarter 2020 results hurt by negative impact of the coronavirus pandemic.
Waters (WAT) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of -19.01% and -6.86%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Waters (WAT) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) first-quarter 2020 results are likely to reflect new product introductions and large molecule strength. However, uncertainties in China and coronavirus woes are concerns.
Waters (WAT) Down 5.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FormFactor (FORM) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
FormFactor's (FORM) fourth-quarter results are driven by strong demand for both Foundry & Logic probe cards.
KLA Corp. (KLAC) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
KLA Corp. (KLAC) reports solid fiscal Q2 results driven by a strong process control market, revenue diversification and expanding demand at the trailing edge nodes.
Waters (WAT) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Waters' (WAT) fourth-quarter 2019 results benefit from solid momentum in governmental & academic market. However, softness in pharmaceutical and industrial markets remains a concern.
Woodward (WWD) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Woodward (WWD) fiscal Q1 results reflect year-over-year increase in income and revenues, primarily driven by sustained global passenger growth and robust sales volume in Aerospace segment.
Waters (WAT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Waters (WAT) delivered earnings and revenue surprises of 5.96% and 0.33%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?